Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
33 Results for "
active doxorubicin
" in MedChemExpress (MCE) Product Catalog:
Products (33)
33 Results for "active doxorubicin" in MCE Product Catalog:
5
4
Target:
Research Areas:
Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
4
4 Cited Publications
Cat. No.: HY-17507A
CAS No.: 138786-67-1
Synonyms: BY1023 sodium; SKF96022 sodium
Target:
Research Areas:
Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
4
4 Cited Publications
Cat. No.: HY-17507B
CAS No.: 164579-32-2
Synonyms: BY1023 sodium hydrate; SKF96022 sodium hydrate
Target:
Research Areas:
Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
2
Category:
Alkaloids Human Gut Microbiota Metabolites Metabolic Disease Endogenous metabolite Disease Research Fields Indole Alkaloids
Target:
2
1
Research Areas:
Zofenopril Calcium (SQ26991) is an orally active angiotensin-converting enzyme (ACE) inhibitor with antioxidant activity and cardioprotective effects. Zofenopril Calcium reduces ROS production and GSH consumption and helps inhibit foam cell formation, thus slowing the progression of atherosclerosis. Zofenopril Calcium prevents cardiac damage caused by chronic Doxorubicin (HY-15142A) .
Cat. No.: HY-173572
CAS No.: 433953-86-7
Research Areas:
SKLB-11A is a selective, orally active and allosteric SIRT3 (sirtuin 3) agonist with a Kd value of 4.7 μM. SKLB-11A is highly selective for other members of the SIRT family. SKLB-11A activates autophagy-related signaling pathways, prevents mitochondrial dysfunction, improves cardiac function in Doxorubicin (HY-15142A)-induced cardiotoxicity and myocardial ischemia/reperfusion models .
Synonyms: Ro 115-1240
Target:
Research Areas:
Dabuzalgron (Ro 115-1240) is an orally active and selective α-1A adrenergic receptor agonist for the treatment of urinary incontinence. Dabuzalgron protects against Doxorubicin-induced cardiotoxicity by preserving mitochondrial function .
Cat. No.: HY-N0566
CAS No.: 85999-40-2
Synonyms: Anemosapogenin
Cat. No.: HY-171955
CAS No.: 315705-04-5
Research Areas:
LXG6403 is an orally active and irreversible LOX inhibitor (IC50 = 1.3 μM). LXG6403 is ~3.5-fold more specific for LOX than LOXL2 and does not inhibit LOXL1. LXG6403 inhibits FAK signaling and induces ROS generation and DNA damage, leading to G1 arrest and apoptosis in chemoresistant triple-negative breast cancer (TNBC) cell lines. LXG6403 alters the extracellular matrix (ECM) and collagen structure, reducing collagen cross-linking and deposition, thereby increasing drug penetration and reducing tumor stiffness. LXG6403 overcomes Doxorubicin (HY-15142) resistance in chemoresistant TNBC PDX in vivo and can be used to study high-stiffness resistant tumors .
Cat. No.: HY-W009356
CAS No.: 34760-60-6
Research Areas:
Cat. No.: HY-17507AR
CAS No.: 138786-67-1
Synonyms: BY1023 sodium (Standard); SKF96022 sodium (Standard)
Research Areas:
Pantoprazole (sodium) (Standard) is the analytical standard of Pantoprazole (sodium). This product is intended for research and analytical applications. Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
Cat. No.: HY-P10759
CAS No.: 372491-73-1
Research Areas:
DNA-PK-IN-8 is a highly potent, selective and orally active DNA-dependent protein kinase (DNA-PK) inhibitor with an IC50 value of 0.8 nM. DNA-PK-IN-8 exhibits synergistic antiproliferative activity against a series of cancer cell lines and significantly suppresses HL-60 tumor growth, when using in combination with Doxorubicin .
Cat. No.: HY-145427
CAS No.: 1257235-99-6
NU5455 is a potent, selective, and orally active inhibitor of DNA-PKcs. NU5455 administration increases both the efficacy and the toxicity of a parenterally administered topoisomerase inhibitor. NU5455 enhances the activity of Doxorubicin released locally in liver tumor xenografts without inducing any adverse effect .
Cat. No.: HY-129410
CAS No.: 75459-34-6
Target:
Research Areas:
ADR-925 is an active chelated iron metabolite with the ability to protect neonatal rat cardiomyocytes from doxorubicin (HY-15142A)-induced damage .
Cat. No.: HY-17507S
CAS No.: 922727-65-9
Synonyms: BY1023-d6; SKF96022-d6
Cat. No.: HY-17507R
CAS No.: 102625-70-7
Synonyms: BY1023 (Standard); SKF96022 (Standard)
Research Areas:
Pantoprazole (Standard) is the analytical standard of Pantoprazole. This product is intended for research and analytical applications. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
Cat. No.: HY-17507BR
CAS No.: 164579-32-2
Synonyms: BY1023 sodium hydrate (Standard); SKF96022 sodium hydrate (Standard)
Research Areas:
Pantoprazole (sodium hydrate) (Standard) is the analytical standard of Pantoprazole (sodium hydrate). This product is intended for research and analytical applications. Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
